Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular dementia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• Between the ages of 50 and 85 years old

• Have contact with a responsible caregiver 3 or more days per week

• Be male or a female who is surgically sterilized or one year post menopausal

Exclusion Criteria:

• Current diagnosis of severe or unstable cardiovascular or other diseases

• Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease